Guided Therapeutics (GTHP) Payables (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Payables data on file, last reported at $2.8 million in Q4 2025.

• For the quarter ending Q4 2025, Payables rose 23.73% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (up 23.73% YoY), and the FY2025 full-year result was $2.8 million, up 23.73% from the prior year.
• Payables rose to $2.8 million in Q4 2025, from $2.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $2.8 million in Q3 2022 to a low of $1.9 million in Q1 2024.
• A 5-year average of $2.3 million and a median of $2.3 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables dropped 28.4% in 2021 and climbed 25.95% in 2022, its largest moves.
• Tracing GTHP's Payables over 5 years: stood at $2.5 million in 2021, then decreased by 11.1% to $2.2 million in 2022, then fell by 11.23% to $2.0 million in 2023, then grew by 12.15% to $2.2 million in 2024, then increased by 23.73% to $2.8 million in 2025.
• Business Quant data shows GTHP's Payables at $2.8 million in Q4 2025, $2.5 million in Q3 2025, and $2.3 million in Q2 2025.